The company has a platform for cell-free DNA testing for prenatal tests, cancer diagnostics and rejection assessments for ...

AUSTIN, Texas, Nov. 2, 2022 /PRNewswire/ -- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was awarded a nationwide contract, effective ...

Natera says it has begun making good on its priorities for 2021, which include expansions in noninvasive prenatal testing (NIPT), transplant rejection testing, minimal residual disease (MRD) cancer ...

SAN CARLOS, Calif., Dec. 19, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination ...

If you are wondering whether Natera's share price still makes sense after such a big run, you are not alone. This breakdown is designed to help you decide if the current price offers genuine value or ...

SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative ...

US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...

Expansion to average-risk groups is quickly driving up "account receivable". Margin and average selling price are both under pressure. Aggressive billing policy implies headline risk and leads to ...

FIRST ON FOX: A tech watchdog has filed a complaint letter with the Securities and Exchange Commission (SEC), alleging that biotech firm Natera misled the public about its prenatal screening ...

Natera presented additional data from an ongoing clinical study of the company’s non-invasive prenatal screening test that demonstrates consistently high detection of chromosomal abnormalities from ...

At baseline, approximately 92% of patients were MRD-negative and had excellent outcomes, with a 5-year distant recurrence-free interval (DRFI) of 93%. Measured starting at EOT, MRD-negative patients ...

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, and Tesis Labs, a US multi-region lab ...